Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Immunotherapy for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Current Evidence and Challenges. Local targets link to admitted publications; unresolved targets remain external evidence.
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
10.1016/j.jhep.2021.11.018 · 2022 · External reference
Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation
10.1016/j.tranon.2022.101603 · 2023 · External reference
Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation
10.1097/sla.0000000000001894 · 2017 · External reference
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review
10.3748/wjg.v21.i39.11185 · 2015 · External reference
Sirolimus use in liver transplant recipients with hepatocellular carcinoma
10.1097/tp.0000000000000965 · 2016 · External reference
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant
10.1001/jamaoncol.2016.5116 · 2017 · External reference
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
10.1056/nejmoa1915745 · 2020 · External reference
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
2022 · External reference
Current landscape of immune checkpoint inhibitor therapy for hepatocellular carcinoma
10.3390/curroncol30060439 · 2023 · External reference
Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry?
10.1111/liv.15474 · 2023 · External reference
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
10.1097/hep.0000000000000466 · 2023 · External reference
Programmed death receptor(PD)-1 monoclonal antibody-induced acute immune hepatitis in the treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report
2016 · External reference
Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient
10.1053/j.gastro.2017.01.063 · 2017 · External reference
Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma
10.1002/pbc.26682 · 2017 · External reference
Pembrolizumab monotherapy in relapsed hepatocellular carcinoma post living donor liver transplantation and sorafenib
2018 · External reference
Preserved liver transplant after PD-1 pathway inhibitor for Hepatocellular Carcinoma
10.1038/ajg.2017.387 · 2017 · External reference
Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: The mayo clinic experience
10.21037/jgo.2018.07.05 · 2018 · External reference
Liver allograft failure after nivolumab treatment—A case report with systematic literature research
10.1097/txd.0000000000000814 · 2018 · External reference
A Case of Hepatocellular carcinoma (HCC) immunotherapy inducing liver transplant rejection
10.14309/00000434-201810001-02415 · 2018 · External reference
Pembrolizumab for metastatic HCC after liver transplantation: The silver bullet?
10.1002/hep.29575 · 2018 · External reference
Anti-programmed cell death protein 1 immuno-therapy for metastatic hepatocellular carcinoma after liver transplantation: A report of three cases
2020 · External reference
Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab
10.1016/j.jceh.2019.11.009 · 2020 · External reference
Nivolumab-induced autoimmune-like cholestatic hepatitis in a liver transplant recipient
10.14309/crj.0000000000000416 · 2020 · External reference
Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis
10.1002/cncr.33134 · 2020 · External reference
Ipilimumab for hepatocellular cancer in a liver transplant recipient
10.2217/imt-2020-0014 · 2020 · External reference
Immune checkpoint inhibitor for HCC recurrence after liver transplantation
10.1016/j.hbpd.2019.09.011 · 2020 · External reference
Immunotherapy after liver transplantation: Where are we now?
10.4240/wjgs.v13.i10.1267 · 2021 · External reference
Extending the use of atezolizumab and bevacizumab to a liver transplant recipient: Need for a post-transplant registry
10.1002/lt.26011 · 2021 · External reference
Immune checkpoint inhibitors in liver transplant: A case series
10.21037/jgo-22-922 · 2023 · External reference
The Safety and Efficacy of Atezolizumab for Recurrent Primary Liver Cancer after Liver Transplantation
10.1007/s12672-025-02299-4 · 2025 · External reference
Standardized Immunosuppressive Protocol to Prevent Rejection under Immunotherapy for Post Liver Transplantation HCC Recurrence: A French Center’s Experience
10.1016/j.liver.2024.100252 · 2025 · External reference
Immune checkpoint inhibitors after liver transplantation: The role of immunosuppressive management
10.1016/j.ajt.2026.02.010 · 2026 · External reference
10.3390/cancers17101650
10.3390/cancers17101650 · External reference
10.3390/jcm14197009
10.3390/jcm14197009 · External reference
10.3390/cancers18081282
10.3390/cancers18081282 · External reference
10.3390/ijms24032358
10.3390/ijms24032358 · External reference
Suppressing, Stimulating and/or Inhibiting: The Evolving Management of HCC Patients after Liver Transplantation
10.1016/j.critrevonc.2024.104607 · 2025 · External reference
Mechanism, Potential, and Concerns of Immunotherapy for Hepatocellular Carcinoma and Liver Transplantation
10.2174/0118761429310703240823045808 · 2024 · External reference
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
10.1111/liv.15419 · 2023 · External reference
Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade
10.1111/ctr.70313 · 2025 · External reference
10.3390/cancers15184574
10.3390/cancers15184574 · External reference
Hepatocellular Carcinoma and Liver Transplant: What about Neo- and Adjuvant Immunotherapy?
10.1016/j.hbpd.2025.10.004 · 2026 · External reference
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant
10.1001/jamaoncol.2016.5116 · ExternalCitation · doi-reference
Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis
10.1002/cncr.33134 · ExternalCitation · doi-reference
Pembrolizumab for metastatic HCC after liver transplantation: The silver bullet?
10.1002/hep.29575 · ExternalCitation · doi-reference
Extending the use of atezolizumab and bevacizumab to a liver transplant recipient: Need for a post-transplant registry
10.1002/lt.26011 · ExternalCitation · doi-reference
Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma
10.1002/pbc.26682 · ExternalCitation · doi-reference
The Safety and Efficacy of Atezolizumab for Recurrent Primary Liver Cancer after Liver Transplantation
10.1007/s12672-025-02299-4 · ExternalCitation · doi-reference
Immune checkpoint inhibitors after liver transplantation: The role of immunosuppressive management
10.1016/j.ajt.2026.02.010 · ExternalCitation · doi-reference
Suppressing, Stimulating and/or Inhibiting: The Evolving Management of HCC Patients after Liver Transplantation
10.1016/j.critrevonc.2024.104607 · ExternalCitation · doi-reference
Immune checkpoint inhibitor for HCC recurrence after liver transplantation
10.1016/j.hbpd.2019.09.011 · ExternalCitation · doi-reference
Hepatocellular Carcinoma and Liver Transplant: What about Neo- and Adjuvant Immunotherapy?
10.1016/j.hbpd.2025.10.004 · ExternalCitation · doi-reference
Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab
10.1016/j.jceh.2019.11.009 · ExternalCitation · doi-reference
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
10.1016/j.jhep.2021.11.018 · ExternalCitation · doi-reference
Standardized Immunosuppressive Protocol to Prevent Rejection under Immunotherapy for Post Liver Transplantation HCC Recurrence: A French Center’s Experience
10.1016/j.liver.2024.100252 · ExternalCitation · doi-reference
Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation
10.1016/j.tranon.2022.101603 · ExternalCitation · doi-reference
Preserved liver transplant after PD-1 pathway inhibitor for Hepatocellular Carcinoma
10.1038/ajg.2017.387 · ExternalCitation · doi-reference
Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient
10.1053/j.gastro.2017.01.063 · ExternalCitation · doi-reference
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
10.1056/nejmoa1915745 · ExternalCitation · doi-reference
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
10.1097/hep.0000000000000466 · ExternalCitation · doi-reference
Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation
10.1097/sla.0000000000001894 · ExternalCitation · doi-reference
Sirolimus use in liver transplant recipients with hepatocellular carcinoma
10.1097/tp.0000000000000965 · ExternalCitation · doi-reference
Liver allograft failure after nivolumab treatment—A case report with systematic literature research
10.1097/txd.0000000000000814 · ExternalCitation · doi-reference
Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade
10.1111/ctr.70313 · ExternalCitation · doi-reference
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
10.1111/liv.15419 · ExternalCitation · doi-reference
Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry?
10.1111/liv.15474 · ExternalCitation · doi-reference
A Case of Hepatocellular carcinoma (HCC) immunotherapy inducing liver transplant rejection
10.14309/00000434-201810001-02415 · ExternalCitation · doi-reference
Nivolumab-induced autoimmune-like cholestatic hepatitis in a liver transplant recipient
10.14309/crj.0000000000000416 · ExternalCitation · doi-reference
Immune checkpoint inhibitors in liver transplant: A case series
10.21037/jgo-22-922 · ExternalCitation · doi-reference
Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: The mayo clinic experience
10.21037/jgo.2018.07.05 · ExternalCitation · doi-reference
Mechanism, Potential, and Concerns of Immunotherapy for Hepatocellular Carcinoma and Liver Transplantation
10.2174/0118761429310703240823045808 · ExternalCitation · doi-reference
Ipilimumab for hepatocellular cancer in a liver transplant recipient
10.2217/imt-2020-0014 · ExternalCitation · doi-reference
10.3390/cancers15184574
10.3390/cancers15184574 · ExternalCitation · doi-reference
10.3390/cancers17101650
10.3390/cancers17101650 · ExternalCitation · doi-reference
10.3390/cancers18081282
10.3390/cancers18081282 · ExternalCitation · doi-reference
Current landscape of immune checkpoint inhibitor therapy for hepatocellular carcinoma
10.3390/curroncol30060439 · ExternalCitation · doi-reference
10.3390/ijms24032358
10.3390/ijms24032358 · ExternalCitation · doi-reference
10.3390/jcm14197009
10.3390/jcm14197009 · ExternalCitation · doi-reference
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review
10.3748/wjg.v21.i39.11185 · ExternalCitation · doi-reference
Immunotherapy after liver transplantation: Where are we now?
10.4240/wjgs.v13.i10.1267 · ExternalCitation · doi-reference
